Literature DB >> 30190822

The role of chemotherapy in the modern management of melanoma.

Rebecca Jane Lee1,2,1,2, Noor Ul-Ain-Tariq1,1, Alberto Fusi1,1, Samantha Bowyer1,1, Paul Lorigan1,2,1,2.   

Abstract

The last 4 years have seen dramatic changes in the treatment of advanced melanoma, largely based on advances in targeted therapy and immunotherapy. This article examines the role of chemotherapy in the modern management of melanoma. We examine the evidence for promising new agents and discuss their position in the sequencing of treatment options for patients with advanced disease. In addition, we discuss the combination of chemotherapy with targeted treatments and immune therapies. Finally, we discuss future areas of research for ensuring that we maximize the potential of all agents available to us and identify new, effective treatments.

Entities:  

Keywords:  advances; biochemotherapy; chemotherapy; melanoma

Year:  2014        PMID： 30190822      PMCID： PMC6094611          DOI： 10.2217/mmt.14.20

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


  52 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

Authors:  A Gupta; S Love; A Schuh; M Shanyinde; J M Larkin; R Plummer; P D Nathan; S Danson; C H Ottensmeier; P Lorigan; L Collins; A Wise; R Asher; R Lisle; M R Middleton
Journal:  Ann Oncol       Date:  2014-02-24       Impact factor: 32.976

3.  Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

Authors:  Anna Maria Di Giacomo; Paolo A Ascierto; Lorenzo Pilla; Mario Santinami; Pier Francesco Ferrucci; Diana Giannarelli; Antonella Marasco; Licia Rivoltini; Ester Simeone; Stefania Vl Nicoletti; Ester Fonsatti; Diego Annesi; Paola Queirolo; Alessandro Testori; Ruggero Ridolfi; Giorgio Parmiani; Michele Maio
Journal:  Lancet Oncol       Date:  2012-08-13       Impact factor: 41.316

4.  Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.

Authors:  P B Chapman; L H Einhorn; M L Meyers; S Saxman; A N Destro; K S Panageas; C B Begg; S S Agarwala; L M Schuchter; M S Ernstoff; A N Houghton; J M Kirkwood
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

Review 5.  Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets.

Authors:  D Grossman; D C Altieri
Journal:  Cancer Metastasis Rev       Date:  2001       Impact factor: 9.264

Review 6.  Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

Authors:  Thomas K Eigentler; Ulrich M Caroli; Peter Radny; Claus Garbe
Journal:  Lancet Oncol       Date:  2003-12       Impact factor: 41.316

7.  Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.

Authors:  R O Johnson; G Metter; W Wilson; G Hill; E Krementz
Journal:  Cancer Treat Rep       Date:  1976-02

8.  Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.

Authors:  Erin R Gardner; William L Dahut; Charity D Scripture; Jacquin Jones; Jeanny B Aragon-Ching; Neil Desai; Michael J Hawkins; Alex Sparreboom; William D Figg
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.

Authors:  M F Avril; S Aamdal; J J Grob; A Hauschild; P Mohr; J J Bonerandi; M Weichenthal; K Neuber; T Bieber; K Gilde; V Guillem Porta; J Fra; J Bonneterre; P Saïag; D Kamanabrou; H Pehamberger; J Sufliarsky; J L Gonzalez Larriba; A Scherrer; Y Menu
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.